New data show significant improvements in lung function using combination of tiotropium and olodaterol* in COPD patients

Tue, 09/04/2012 - 1:25am
Boehringer Ingelheim

Ingelheim, Germany, 3rd September, 2012 – New phase II data presented for the first time today at the 2012 European Respiratory Society (ERS) congress show that combining tiotropium with olodaterol significantly improved lung function (FEV1 ) over 24 hours in COPD patients compared to olodaterol alone.1

Significant improvements were seen for all combinations of doses tested (tiotropium 1.25, 2.5 and 5 μg / olodaterol 5 μg, 10 μg) compared with the respective olodaterol monotherapies.1 Both treatments were administered using the patient-preferred2-5 Respimat® Soft MistTM Inhaler (SMI) device.

After 4 weeks of treatment, the combination of tiotropium and olodaterol provided an average lung function improvement compared to the pre-treatment baseline of up to 342 mL over the first 6 hours (FEV1 AUC0-6) and improvements in trough FEV1 of up to 166 mL.

Compared to olodaterol monotherapy, the combination of tiotropium and olodaterol further increased lung function by up to 144 mL (FEV1 AUC0-6) and 84 mL (trough FEV1).



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.